The key finding
A 2025 consensus panel at the Diabetes UK conference revealed a critical shortage of research guiding care for women with early-onset type 2 diabetes (EOT2D) throughout pregnancy and surrounding periods. After reviewing three systematic analyses covering interventional, observational, and qualitative studies, experts concluded that evidence is especially scarce for preconception and postnatal care. The few pregnancy studies that exist are typically small-scale with limited applicability across different populations. This research gap comes at a time when EOT2D prevalence is rising, putting more women and their babies at risk for adverse outcomes.
What the study looked like
This was a consensus statement developed through a structured process rather than a single experimental study. Researchers conducted three systematic reviews examining all available literature on EOT2D management across the reproductive life course—covering intervention trials, observational data, and qualitative research capturing patient experiences. These findings were presented at the Diabetes UK Annual Professional Conference in Glasgow in February 2025, where an expert panel discussed the evidence with audience participation. The consensus statement specifically addressed research priorities identified by the James Lind Alliance priority-setting partnership in diabetes in pregnancy, which incorporates patient perspectives to determine what questions matter most to those living with the condition.
Why researchers think this happened
The panel identified that most existing pregnancy research focuses on medication use and continuous glucose monitoring, but these studies remain limited in scope and size. The observational evidence suggests three key factors appear linked to better outcomes: maintaining optimal blood sugar control, addressing maternal body mass index, and preventing excessive weight gain during pregnancy. Qualitative research revealed that women with EOT2D experience significant psychological burden during pregnancy and feel they lack adequate support systems. The consensus group hypothesized that the research gap exists partly because EOT2D in younger women is a relatively recent phenomenon, and traditional diabetes research has focused more heavily on type 1 diabetes in pregnancy or gestational diabetes, leaving this growing population understudied.
How to read this carefully
This consensus statement identifies research gaps rather than presenting new experimental findings, so readers should understand it as a roadmap for future investigation rather than definitive guidance. The panel’s conclusions are based on systematic reviews, but the underlying problem is that those reviews found relatively few high-quality studies to analyze—particularly for preconception and postnatal periods. The observational associations between glycemic control, weight management, and outcomes do not establish causation and may reflect confounding factors like access to healthcare or socioeconomic status. Additionally, the panel noted that existing studies often lack generalizability across different cultural and ethnic groups, meaning findings from one population may not apply universally.
What this means for everyday life
For women with EOT2D who are considering pregnancy or currently pregnant, this consensus statement highlights both a challenge and an advocacy opportunity. The scarcity of research means clinical guidance may be based on extrapolation from other diabetes types rather than evidence specific to EOT2D. Women in this situation might consider asking their healthcare providers about participating in research studies to help build the evidence base. The emphasis on preconception and postnatal care suggests these periods deserve particular attention in conversations with medical teams, even though standard protocols may focus primarily on pregnancy itself. Given the identified gaps, women with EOT2D may benefit from seeking specialized diabetes-pregnancy care teams and advocating for comprehensive support that extends beyond the nine months of pregnancy to include family planning and postpartum follow-up.